Researchers at Stanford Medicine have made significant progress toward developing a universal vaccine that could protect against a variety of respiratory pathogens. In a recent study published in Science, scientists created an experimental vaccine that is administered intranasally and has shown promise in providing long-lasting protection in mice against viruses like SARS-CoV-2, as well as certain bacteria and allergens.
This novel vaccine operates differently from traditional vaccines, which typically focus on specific antigens from pathogens. Instead, it mimics the communication signals used by immune cells during infections, activating both the innate and adaptive immune systems. While existing vaccines primarily stimulate the adaptive immune response, which targets specific pathogens, this new approach leverages the innate immune system's broader capabilities. Researchers found that the vaccine could sustain an elevated innate immune response for months, significantly enhancing the body’s ability to fend off infections.
In the study, vaccinated mice exhibited substantial protection from respiratory viruses and bacteria, and when exposed to allergens, they showed a reduced allergic response compared to unvaccinated mice. These findings suggest that a single vaccine could reduce the need for multiple yearly vaccinations and provide rapid protection against emerging infectious threats.
The next steps involve human trials to assess safety and efficacy, with hopes that a universally protective vaccine could be available within five to seven years. If successful, this vaccine could potentially transform seasonal vaccination practices and enhance preparedness for future pandemics. The research was supported by various funding sources, including the National Institutes of Health.